布洛芬与烧伤患者皮肤移植中出血风险或输血需求增加无关
回顾性病例对照图表审查纳入2024年1月1日至7月31日急性烧伤并接受皮肤移植的53例患者,其中24例(45.2%)住院期间接受计划性布洛芬治疗。围术期输血需求、皮肤移植失败率及术后并发症在两组间均无显著差异,未发生超敏反应或胃肠道出血。
要点
- 布洛芬组与非布洛芬组围术期浓缩红细胞输注量无显著差异(3.2±2.8单位 vs 4.6±3.1单位,P=.207)。
- 皮肤移植失败(需再次移植)非布洛芬组6.9%(n=2)vs 布洛芬组0%(n=0),P=.112。
- 血清肿、血肿、感染等术后并发症两组无显著差异,无超敏反应或胃肠道出血病例。
核心结论
- 烧伤患者服用布洛芬可能不增加出血或皮肤移植失败风险,提示此类药物在该情境下可能是安全的。
研究设计与样本
- 回顾性病例对照图表审查,纳入2024年1月1日至7月31日因急性烧伤入院并接受皮肤移植的患者,共53例符合纳入标准,其中24例(45.2%)住院期间接受计划性布洛芬治疗。
主要发现
- 非布洛芬组与布洛芬组总面积烧伤分别为12.3±9.3%和14.3±12.1%(P=.62)。
- 非布洛芬组79.3%患者接受网状移植,布洛芬组为79.2%(P=.734)。
- 围术期输血需求两组相似,非布洛芬组平均4.6±3.1单位浓缩红细胞,布洛芬组3.2±2.8单位(P=.207)。
- 皮肤移植失败(定义为需再次移植)非布洛芬组6.9%(n=2),布洛芬组0%(n=0)(P=.112)。
- 术后血清肿(P=.259)、血肿(P=.498)、感染(P=.568)两组无显著差异;无超敏反应或胃肠道出血病例。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ibuprofen, a non-steroidal anti-inflammatory drug, can increase the risk of bleeding, a significant concern in burn surgery, which often involves substantial blood loss. This study aims to evaluate the safety of ibuprofen use in burn patients undergoing skin grafting. A retrospective case-control chart review was conducted for patients admitted with acute burn injury from January 1, 2024 to July 31, 2024 who underwent skin grafting. The primary outcome variables included perioperative transfusion requirement, bleeding, skin graft failure, and other complications. A total of 53 patients met the inclusion criteria, 24 (45.2%) of whom received scheduled ibuprofen therapy during their hospitalization. The total body surface area affected was 12.3 ± 9.3% for the non-ibuprofen group and 14.3 ± 12.1% for the ibuprofen group (P = .62). A total of 79.3% of patients in the non-ibuprofen group received meshed grafts compared to 79.2% in the ibuprofen group (P = .734). Perioperative transfusion requirements were similar between the 2 cohorts, averaging 4.6 ± 3.1 for the non-ibuprofen group and 3.2 ± 2.8 units of packed red blood cells for the ibuprofen group (P = .207). Skin graft failure (defined as the need for re-grafting) occurred in 6.9% (n = 2) of the non-ibuprofen cohort vs none (n = 0) in the ibuprofen group (P = .112). Postoperative complications did not vary significantly between the 2 groups for seroma (P = .259), hematoma (P = .498), and infection (P = .568). There were no cases of hypersensitivity or gastrointestinal bleeding. There is likely no increased risk of bleeding or skin graft failure in burn injury patients taking ibuprofen, suggesting that these medications may be safe in this context.
引用
- Manasyan A, Gasho JO, Kim MI, et al. Ibuprofen is Not Associated With an Elevated Bleeding Risk or Transfusion Requirement in Skin Grafting for Patients With Burn Injuries. J Burn Care Res. 2025. PMID: 40036242. doi:10.1093/jbcr/iraf015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。